ASH 2018 | Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS
Saar Gill
• 15 Jan 2019
In this interview, Saar Gill, MD, PhD, from the University of Pennsylvania, Philadelphia, PA., discusses a retrospective review looking at the outcomes for patients with either acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) receiving allogeneic stem cell transplants (allo-SCT) based on pre-transplant measurable residual disease (MRD) status determined by next-generation sequencing (NGS). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dr Gill reveals similar outcomes are observed regardless of molecular MRD findings for the patients, meaning a patient does not need an MRD negative complete response prior to transplant to benefit from this treatment.
